Articles

Search Articles

Advanced search
Help

Catalogue

Articles

Databases

X
Search Filters
Format Format
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
humans (28) 28
oncology (28) 28
index medicus (27) 27
female (16) 16
aged (11) 11
adult (10) 10
breast cancer (10) 10
chemotherapy (10) 10
middle aged (9) 9
breast neoplasms - drug therapy (8) 8
cancer (8) 8
aged, 80 and over (7) 7
antineoplastic combined chemotherapy protocols - therapeutic use (7) 7
breast neoplasms - pathology (7) 7
cancer therapies (7) 7
retrospective studies (7) 7
american society (6) 6
male (6) 6
patients (6) 6
treatment outcome (6) 6
united states (6) 6
adolescent (5) 5
breast neoplasms - mortality (5) 5
kaplan-meier estimate (5) 5
neoplasm staging (5) 5
neoplasms (5) 5
survival (5) 5
therapy (5) 5
artists (4) 4
breast (4) 4
drug administration schedule (4) 4
drugs (4) 4
medicare (4) 4
metastasis (4) 4
survival analysis (4) 4
women (4) 4
young adult (4) 4
antineoplastic combined chemotherapy protocols - adverse effects (3) 3
care (3) 3
care and treatment (3) 3
chemotherapy, adjuvant (3) 3
combination (3) 3
comorbidity (3) 3
cost reduction (3) 3
costs (3) 3
disease-free survival (3) 3
evidence-based medicine (3) 3
follow-up (3) 3
medical screening (3) 3
mortality (3) 3
neoplasms - epidemiology (3) 3
third party (3) 3
trastuzumab (3) 3
abstracts (2) 2
antineoplastic agents - administration & dosage (2) 2
antineoplastic agents - adverse effects (2) 2
antineoplastic agents - therapeutic use (2) 2
antineoplastic combined chemotherapy protocols - administration & dosage (2) 2
architects (2) 2
art (2) 2
asco special (2) 2
asco special articles (2) 2
association (2) 2
bevacizumab (2) 2
biomarkers, tumor - analysis (2) 2
breast neoplasms - chemistry (2) 2
breast neoplasms - genetics (2) 2
cancer informatics (2) 2
carboplatin - administration & dosage (2) 2
cell lymphoma (2) 2
community health services (2) 2
comparative effectiveness (2) 2
databases, factual (2) 2
deoxyribonucleic acid--dna (2) 2
diffusion-weighted mri (2) 2
docetaxel (2) 2
dose-response relationship, drug (2) 2
dynamic contrast-enhanced mri (2) 2
electronic health records (2) 2
endocrine therapy (2) 2
erbb-2 protein (2) 2
follow-up studies (2) 2
gemcitabine (2) 2
genomics (2) 2
health aspects (2) 2
health care costs (2) 2
health information technology (2) 2
health status disparities (2) 2
healthcare disparities (2) 2
hematology (2) 2
incidence (2) 2
informatics (2) 2
lapatinib plus capecitabine (2) 2
magnetic resonance imaging (2) 2
medical oncology - trends (2) 2
medicine, general & internal (2) 2
metaanalysis (2) 2
metastases (2) 2
metastatic breast cancer (2) 2
neoplasm metastasis (2) 2
more...
Language Language
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


1. Debra Patt on How the Management of Cancer is Changing as Patients Live Longer
by Patt, Debra
Oncology (Williston Park, N.Y.), ISSN 0890-9091, 06/2018, Volume 32, Issue 6, pp. 274 - 275
ONCOLOGY | Cancer Survivors | Survival Rate - trends | Humans | Medical Oncology - trends | Aftercare - trends | Neoplasms - mortality | Molecular Targeted Therapy | Neoplasms - drug therapy
Journal Article
Details down arrow
2. Full Text Neratinib after trastuzumab-based adjuvant therapy in HER2-positive breast cancer (ExteNET): 5-year analysis of a randomised, double-blind, placebo-controlled, phase 3 trial
by Martin, Miguel and Holmes, Frankie A and Ejlertsen, Bent and Delaloge, Suzette and Moy, Beverly and Iwata, Hiroji and von Minckwitz, Gunter and Chia, Stephen K L and Mansi, Janine and Barrios, Carlos H and Gnant, Michael and Tomašević, Zorica and Denduluri, Neelima and Šeparović, Robert and Gokmen, Erhan and Bashford, Anna and Ruiz Borrego, Manuel and Kim, Sung-Bae and Kim, Seung Jin and Jakobsen, Erik Hugger and Ciceniene, Audrone and Inoue, Kenichi and Overkamp, Friedrich and Heijns, Joan B and Armstrong, Anne C and Link, John S and Joy, Anil Abraham and Bryce, Richard and Wong, Alvin and Moran, Susan and Yao, Bin and Xu, Feng and Xu, Binghe and Auerbach, Alan and Buyse, Marc and Chan, Arlene and Harvey, Vernon and Tomek, Rudolf and Robert, Nicholas J and Gore, Ira and Smith, John W and Smith, Julie C and Masuda, Norikazu and Di Sean Kendall, S and Harker, William Graydon and Petrakova, Katarina and Guerrero Zotano, Angel and Simon, Amparo Ruiz and Konstantinovic, Zora Neskovic and Iannotti, Nicholas O and Tassone, Pierfrancesco and Rodriguez, Gladys I and Jáñez Martinez, Noelia and Crespo Massieu, Carmen and Smickoska, Snezana and Somali, Isil and Yilmaz, Ugur and Alonso, Mirta Garcia and Rosales, Adolfo Murias and Cold, Soeren and Knoop, Ann Soegaard and Patt, Debra and Hellerstedt, Beth A and Morales Murillo, Serafin and Mayer, Ingrid A and Means-Powell, Julie Ann and Hui, Rina and Senecal, Francis M and De Boer, Richard Hendry and Shen, Zhenzhou and Luczak, Adam Andrzej and Chui, Joanna W.Y and Chui, Stephen and Tsang, Janice Wing-hang and Lang, Istvan and Rai, Yoshiaki and Hozumi, Yasuo and Ten Tije, Albert J and Bhandari, Manish and Osborne, Cynthia R.C and Ohtani, Shoichiro and Higaki, Kenji and Watanabe, Junichiro and Watanabe, Kenichi and Taguchi, Tetsuya and Taguchi, Kazunori and Takahashi, Masato and Filipovic, Sladjana and Hansen, Vincent L and Rao, Vijayarama Phooshkooru and Gupta, Manish and Petrov, Petar and Coudert, Bruno and Vojnovic, Zeljko and Polya, Zsofia and Miyaki, Toshiko and Yamamoto, Naohito and Brincat, Stephen and Lesniewski-Kmak, Krzysztof and Chmielowska, Ewa and ... and ExteNET Study Grp and ExteNET Study Group
The Lancet Oncology, ISSN 1470-2045, 12/2017, Volume 18, Issue 12, pp. 1688 - 1700
ExteNET showed that 1 year of neratinib, an irreversible pan-HER tyrosine kinase inhibitor, significantly improves 2-year invasive disease-free survival after... 
LAPATINIB | NCCTG N9831 | NSABP B-31 | HERA TRIAL | MULTICENTER | ONCOLOGY | TYROSINE KINASE | FOLLOW-UP | JOINT ANALYSIS | ESTROGEN-RECEPTOR | CHEMOTHERAPY | Breast Neoplasms - surgery | Antineoplastic Combined Chemotherapy Protocols - administration & dosage | Follow-Up Studies | Humans | Middle Aged | Mastectomy - methods | Receptor, ErbB-2 - metabolism | Antineoplastic Combined Chemotherapy Protocols - adverse effects | Quinolines - administration & dosage | Dose-Response Relationship, Drug | Time Factors | Neoplasm Invasiveness - pathology | Adult | Female | Chemotherapy, Adjuvant | Antibodies, Monoclonal, Humanized - adverse effects | Double-Blind Method | Drug Administration Schedule | Risk Assessment | Administration, Oral | Japan | Kaplan-Meier Estimate | Proportional Hazards Models | Trastuzumab - adverse effects | Treatment Outcome | Trastuzumab - administration & dosage | Breast Neoplasms - drug therapy | Disease-Free Survival | Breast Neoplasms - pathology | Survival Analysis | Breast Neoplasms - mortality | Neoplasm Staging | Quinolines - adverse effects
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
3. Full Text Iniparib plus Chemotherapy in Metastatic Triple-Negative Breast Cancer
by O'Shaughnessy, Joyce and Osborne, Cynthia and Pippen, John E and Yoffe, Mark and Patt, Debra and Rocha, Christine and Koo, Ingrid Chou and Sherman, Barry M and Bradley, Charles
The New England Journal of Medicine, ISSN 0028-4793, 01/2011, Volume 364, Issue 3, pp. 205 - 214
In this phase 2 study, the use of gemcitabine and carboplatin plus iniparib, as compared with gemcitabine and carboplatin alone, resulted in a significantly... 
POLY(ADP-RIBOSE) POLYMERASE | MEDICINE, GENERAL & INTERNAL | PHASE-II TRIAL | GEMCITABINE/CARBOPLATIN | TRASTUZUMAB | SUBTYPES | DNA-DAMAGE | GENE-EXPRESSION | CARCINOMAS | SPORADIC BREAST | TUMORS | Deoxycytidine - administration & dosage | Humans | Kaplan-Meier Estimate | Antineoplastic Combined Chemotherapy Protocols - adverse effects | Carboplatin - administration & dosage | Breast Neoplasms - drug therapy | Poly(ADP-ribose) Polymerase Inhibitors | Cross-Over Studies | Benzamides - therapeutic use | Neoplasm Metastasis - drug therapy | Antineoplastic Combined Chemotherapy Protocols - therapeutic use | Breast Neoplasms - pathology | Adolescent | Survival Analysis | Aged, 80 and over | Adult | Breast Neoplasms - mortality | Female | Aged | Benzamides - adverse effects | Deoxycytidine - analogs & derivatives | Antimitotic agents | Usage | Care and treatment | Chemotherapy | Enzyme inhibitors | Gemcitabine | Breast cancer | Genetic aspects | Drug therapy, Combination | Antineoplastic agents | Health aspects | Cancer | DNA methylation | Cancer therapies | Deoxyribonucleic acid--DNA | Index Medicus | Abridged Index Medicus
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
4. Full Text MONARCH 1, A Phase II Study of Abemaciclib, a CDK4 and CDK6 Inhibitor, as a Single Agent, in Patients with Refractory HR+/HER2(-) Metastatic Breast Cancer
by Dickler, MN and Tolaney, SM and Rugo, HS and Cortes, J and Dieras, V and Patt, D and Wildiers, H and Hudis, CA and O'Shaughnessy, J and Zamora, E and Yardley, DA and Frenzel, M and Koustenis, A and Baselga, J
CLINICAL CANCER RESEARCH, ISSN 1078-0432, 09/2017, Volume 23, Issue 17, pp. 5218 - 5224
Purpose: The phase II MONARCH 1 study was designed to evaluate the single-agent activity and adverse event (AE) profile of abemaciclib, a selective inhibitor... 
EVEROLIMUS PLUS EXEMESTANE | ONCOLOGY | SAFETY | ANTHRACYCLINE | TRANSCRIPTION | ENDOCRINE THERAPY | CELL-CYCLE | CLINICAL-PRACTICE | ASSOCIATION | AMERICAN SOCIETY | CHEMOTHERAPY | Cyclin-Dependent Kinase 6 - antagonists & inhibitors | Aminopyridines - administration & dosage | Prognosis | Receptor, ErbB-2 - genetics | Cyclin-Dependent Kinase 4 - genetics | Humans | Middle Aged | Cyclin-Dependent Kinase 6 - genetics | Aminopyridines - adverse effects | Treatment Outcome | Breast Neoplasms - drug therapy | Drug-Related Side Effects and Adverse Reactions - pathology | Disease-Free Survival | Neoplasm Metastasis | Breast Neoplasms - genetics | Benzimidazoles - administration & dosage | Breast Neoplasms - pathology | Aged, 80 and over | Adult | Female | Aged | Benzimidazoles - adverse effects | Cyclin-Dependent Kinase 4 - antagonists & inhibitors | Drug-Related Side Effects and Adverse Reactions - classification | Slopes | Toxicity | Diarrhea | Fatigue | Nausea | Breast cancer | Metastasis | Cancer therapies | Patients | Survival | ErbB-2 protein | Cyclin-dependent kinase 4 | Metastases | Chemotherapy | Inhibitors | Experimental design | Quality | Medical prognosis | Response rates | Breast | Toxic diseases | Cancer | Index Medicus
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
5. Full Text Better screening using big data
by Patt, Debra
Journal of Oncology Practice, ISSN 1554-7477, 08/2016, Volume 12, Issue 8, pp. 699 - 700
ONCOLOGY
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
6. Understanding Utilization Management Policy: How to Manage This Increasingly Complex Environment in Collaboration and With Better Data
by Patt, Debra A
American Society of Clinical Oncology educational book. American Society of Clinical Oncology. Annual Meeting, 05/2018, Volume 38, Issue 38, pp. 135 - 138
As innovation in cancer care continues and newer costly therapies receive approval, utilization management will continue to grow as an important way that... 
Health Care Costs | Patient Acceptance of Health Care | Health Policy | Patient Care Management | Humans | Quality of Health Care
Journal Article
Details down arrow
7. Full Text Cancer Informatics in 2017: A New Beginning and a Bright Future
by Warner, Jeremy L and Patt, Debra A and Section Editors for the IMIA Yearbook Section on Cancer Informatics
Yearbook of Medical Informatics, ISSN 0943-4747, 08/2018, Volume 27, Issue 1, pp. 223 - 226
Summary Objective:  To summarize significant research contributions on cancer informatics published in 2017. Methods:  An extensive search using... 
Section 11: Cancer Informatics | Medical Informatics | Genomics | Humans | Neoplasms | Section 11 | genomics | informatics | health information technology | data visualization | Cancer Informatics
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
8. Full Text Pooled analysis of long-term survival data from phase II and phase III trials of ipilimumab in unresectable or metastatic melanoma
by Schadendorf, Dirk and Hodi, F. Stephen and Robert, Caroline and Weber, Jeffrey S and Margolin, Kim and Hamid, Omid and Patt, Debra and Chen, Tai-Tsang and Berman, David M and Wolchok, Jedd D
Journal of Clinical Oncology, ISSN 0732-183X, 06/2015, Volume 33, Issue 17, pp. 1889 - 1894
Purpose To provide a more precise estimate of long-term survival observed for ipilimumab-treated patients with advanced melanoma, we performed a pooled... 
EFFICACY | ONCOLOGY | THERAPY | Skin Neoplasms - pathology | Prospective Studies | Skin Neoplasms - drug therapy | Drug Administration Schedule | Follow-Up Studies | Humans | Ipilimumab | Antibodies, Monoclonal - adverse effects | Kaplan-Meier Estimate | Antibodies, Monoclonal - therapeutic use | Treatment Outcome | Antineoplastic Agents - therapeutic use | Antineoplastic Agents - administration & dosage | Melanoma - secondary | Clinical Trials, Phase III as Topic | Antibodies, Monoclonal - administration & dosage | Antineoplastic Agents - adverse effects | Melanoma - drug therapy | Retrospective Studies | Clinical Trials, Phase II as Topic | Original Reports
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
9. Full Text Cancer Informatics in 2018: The Mysteries of the Cancer Genome Continue to Unravel, Deep Learning Approaches the Clinic, and Passive Data Collection Demonstrates Utility
by Warner, Jeremy L and Patt, Debra and Section Editors for the IMIA Yearbook Section on Cancer Informatics
Yearbook of Medical Informatics, ISSN 0943-4747, 08/2019, Volume 28, Issue 1, pp. 236 - 238
Summary Objective : To summarize significant research contributions on cancer informatics published in 2018. Methods : An extensive search using... 
Section 12: Cancer Informatics | genomics | informatics | health information technology | Cancer Informatics | Section 12 | Neoplasms | ontologies
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
10. Survivorship in the community oncology practice
by Patt, Debra A
Community Oncology, ISSN 1548-5315, 2013, Volume 10, Issue 9, p. 253
Journal Article
Details down arrow
11. Full Text MONARCH 1, a phase II study of abemaciclib, a CDK4 and CDK6 inhibitor, as a single agent, n patients with refractory HR+/HER2- metastatic breast cancer
by Dickler, Maura N and Tolaney, Sara M and Rugo, Hope S and Cortes, Javier and Dieras, Veronique and Patt, Debra and Wildiers, Hans and Hudis, Clifford A and O'Shaughnessy, Joyce and Zamora, Esther and Yardley, Denise A and Frenzel, Martin and Koustenis, Andrew and Baselga, Jose
Clinical Cancer Research, ISSN 1078-0432, 09/2017, Volume 23, Issue 17, pp. 5218 - 5224
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
12. Full Text Recent study on site of care has severe limitations
by Gordan, Lucio N and Patt, Debra
The American journal of managed care, 10/2018, Volume 24, Issue 10, p. 450
The outpatient community oncology setting is consistently less costly for cancer treatment as opposed to the outpatient hospital setting. 
Medicare | United States
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
13. Full Text Treatment ofpatients (pts) with HER2- metastatic breast cancer (MBC) with nab-paclitaxel (nab-P) in the clinical practice setting—Results of a US Oncology survey
by Patt, Debra A and Richardson, Paula and Rembert, Debra and Corzo, Deyanira and Chen, Clara
Journal of Clinical Oncology, ISSN 0732-183X, 05/2014, Volume 32, Issue 15_suppl, pp. e12008 - e12008
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
14. Full Text Economic impact of progressive disease (PD) following frontline therapy in classical Hodgkin lymphoma (HL)
by Yasenchak, Christopher A and Tseng, Wan-Yu and Feng, Chunyang and Yap, Mark and Rembert, Debra and Patt, Debra A
Journal of Clinical Oncology, ISSN 0732-183X, 05/2014, Volume 32, Issue 15_suppl, pp. e19538 - e19538
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
15. Full Text Relative dose intensity of first-line chemotherapy and overall survival in patients with advanced non-small-cell lung cancer
by Crawford, Jeffrey and Denduluri, Neelima and Patt, Debra and Jiao, Xiaolong and Morrow, Phuong Khanh and Garcia, Jacob and Barron, Richard and Lyman, Gary H
Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer, ISSN 0941-4355, 06/2019
The effects of chemotherapy dose intensity on survival in patients with advanced non-small-cell lung cancer (NSCLC) are poorly understood. We retrospectively... 
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
16. Full Text Acute Myeloid Leukemia After Adjuvant Breast Cancer Therapy in Older Women: Understanding Risk
by Debra A. Patt and Zhigang Duan and Shenying Fang and Gabriel N. Hortobagyi and Sharon H. Giordano
Journal of Clinical Oncology, ISSN 0732-183X, 09/2007, Volume 25, Issue 25, pp. 3871 - 3876
Purpose The purpose of this study was to determine the risk of developing acute myeloid leukemia ( AML) after adjuvant chemotherapy for breast cancer in older... 
EPIRUBICIN | COLONY-STIMULATING FACTOR | ONCOLOGY | MYELODYSPLASTIC SYNDROME | CHEMOTHERAPY | Multivariate Analysis | Risk Assessment | Humans | Leukemia, Myeloid, Acute - epidemiology | Myelodysplastic Syndromes - epidemiology | Breast Neoplasms - drug therapy | Incidence | Antineoplastic Agents - adverse effects | Chemotherapy, Adjuvant - adverse effects | Myelodysplastic Syndromes - chemically induced | Aged, 80 and over | Female | Registries | Aged | Leukemia, Myeloid, Acute - chemically induced
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
17. Full Text Advanced practice providers and survivorship care plans
by Mikan, Sabrina Q and Carter, Patricia and Patt, Debra A
Journal of Clinical Oncology, ISSN 0732-183X, 01/2016, Volume 34, Issue 3_suppl, pp. 70 - 70
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
18. Full Text Systemic therapy for patients with advanced human epidermal growth factor receptor 2-positive breast cancer: American Society of Clinical Oncology clinical practice guideline
by Giordano, Sharon H and Temin, Sarah and Kirshner, Jeffrey J and Chandarlapaty, Sarat and Crews, Jennie R and Davidson, Nancy E and Esteva, Francisco J and Gonzalez-Angulo, Ana M and Krop, Ian and Levinson, Jennifer and Lin, Nancy U and Modi, Shanu and Patt, Debra A and Perez, Edith A and Perlmutter, Jane and Ramakrishna, Naren and Winer, Eric P and American Society of Clinical Oncology
Journal of Clinical Oncology, ISSN 0732-183X, 07/2014, Volume 32, Issue 19, pp. 2078 - 2099
Purpose To provide evidence-based recommendations to practicing oncologists and others on systemic therapy for patients with human epidermal growth factor... 
SURVIVAL | WOMEN | TRASTUZUMAB | ONCOLOGY | PROGNOSIS | RECOMMENDATIONS | DISEASE | PHASE-II | LAPATINIB PLUS CAPECITABINE | COMBINATION | PERTUZUMAB | Triazoles - administration & dosage | Health Status Disparities | United States | Humans | Receptors, Estrogen - analysis | Nitriles - administration & dosage | Receptors, Progesterone - analysis | Breast Neoplasms - chemistry | Antibodies, Monoclonal, Humanized - administration & dosage | Societies, Medical | Female | Quinazolines - administration & dosage | Clinical Trials as Topic - standards | Molecular Targeted Therapy - methods | Drug Administration Schedule | Biomarkers, Tumor - analysis | Comorbidity | Maytansine - analogs & derivatives | Antineoplastic Agents, Hormonal - administration & dosage | Treatment Outcome | Evidence-Based Medicine | Breast Neoplasms - drug therapy | Taxoids - administration & dosage | Maytansine - administration & dosage | Antineoplastic Combined Chemotherapy Protocols - therapeutic use | Breast Neoplasms - pathology | Healthcare Disparities | Breast Neoplasms - mortality | Receptor, ErbB-2 - analysis | Trastuzumab | Index Medicus | ASCO Special
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
19. Full Text Cardiac Morbidity of Adjuvant Radiotherapy for Breast Cancer
by Debra A. Patt and James S. Goodwin and Yong-Fang Kuo and Jean L. Freeman and Dong D. Zhang and Thomas A. Buchholz and Gabriel N. Hortobagyi and Sharon H. Giordano
Journal of Clinical Oncology, ISSN 0732-183X, 10/2005, Volume 23, Issue 30, pp. 7475 - 7482
Purpose Adjuvant breast irradiation has been associated with an increase in cardiac mortality, because left-sided breast radiation can produce cardiac damage.... 
LONG-TERM SURVIVORS | MYOCARDIAL-INFARCTION | ONCOLOGY | CONSERVING SURGERY | POSTOPERATIVE RADIOTHERAPY | RANDOMIZED-TRIAL | FOLLOW-UP | COMPARING TOTAL MASTECTOMY | PREMENOPAUSAL WOMEN | INDUCED HEART-DISEASE | RADIATION-THERAPY | United States - epidemiology | Breast Neoplasms - radiotherapy | Heart Diseases - etiology | SEER Program | Time Factors | Heart - radiation effects | Radiotherapy, Adjuvant - adverse effects | Humans | Female | Survival Rate | Aged
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
20. Full Text Repeatability, reproducibility, and accuracy of quantitative mri of the breast in the community radiology setting
by Sorace, Anna G and Wu, Chengyue and Barnes, Stephanie L and Jarrett, Angela M and Avery, Sarah and Patt, Debra and Goodgame, Boone and Luci, Jeffery J and Kang, Hakmook and Abramson, Richard G and Yankeelov, Thomas E and Virostko, John
Journal of Magnetic Resonance Imaging, ISSN 1053-1807, 09/2018, Volume 48, Issue 3, pp. 695 - 707
Background: Quantitative diffusion-weighted MRI (DW-MRI) and dynamic contrast-enhanced MRI (DCE-MRI) have the potential to impact patient care by providing... 
breast cancer | diffusion‐weighted MRI | dynamic contrast‐enhanced MRI | T1‐mapping | T1-mapping | dynamic contrast-enhanced MRI | diffusion-weighted MRI | MENSTRUAL-CYCLE | DCE-MRI | THERAPY | NEOADJUVANT CHEMOTHERAPY | CLINICAL-TRIALS | 3 T | PATHOLOGICAL RESPONSE | APPARENT DIFFUSION-COEFFICIENT | ICE-WATER PHANTOM | CANCER | RADIOLOGY, NUCLEAR MEDICINE & MEDICAL IMAGING | Radiology | Analysis | Radiology, Medical | Adipose tissues | Medical research | Adipose tissue | Statistical analysis | Communities | Clinical trials | Breast cancer | Mapping | Statistical tests | Field strength | Accuracy | Maps | Magnetic resonance imaging | Reproducibility | Breast | Diffusion coefficient | Cancer
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
No results were found for your search.

Cannot display more than 1000 results, please narrow the terms of your search.